On May 6, 2026, Swiss pharmaceutical giant Roche announced it had ​agreed to acquire U.S.-based digital ‌pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus ​further milestone payments of up ​to $300 million.

The acquisition builds on a ⁠five-year partnership between Roche and ​PathAI that was scaled up in ​2024 to include the development of AI-enabled companion diagnostic algorithms. The deal is expected to ​close in the second half ​of 2026, and PathAI – based on Boston, Massachusetts – ‌is ⁠due to become part of Roche’s diagnostics division.

Roche said the acquisition strengthens its position in digital pathology, ​which is ​helping ⁠to transform manual workflows into fully automated, AI-driven processes.